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Accepted 16 March 2012; Published online 27 June 2012AbstractObjective: To explore the evidence translation process during a 1-week national guideline development workshop (‘‘Child Health
Evidence Week’’) in Kenya.
Study Design and Setting: Nonparticipant observational study of the discussions of a multidisciplinary guideline development panel in
Kenya. Discussions were aided by GRADE (Grading of Recommendations Assessment, Development, and Evaluation) grid.
Results: Three key thematic categories emerged: 1) ‘‘referral to other evidence to support or refute the proposed recommendations;’’
2) ‘‘assessment of the presented research evidence;’’ and 3) ‘‘assessment of the local applicability of evidence.’’ The types of evidence cited
included research evidence and anecdotal evidence based on clinician experiences. Assessment of the research evidence revealed important
challenges in the translation of evidence into recommendations, including absence of evidence, low quality or inconclusive evidence,
inadequate reporting of key features of the management under consideration, and differences in panelists’ interpretation of the research
literature. A broad range of factors with potential to affect local applicability of evidence were discussed.
Conclusion: The process of the ‘‘Child Health Evidence Week’’ combined with the GRADE grid may aid transparency in the delib-
erative process of guideline development, and provide a mechanism for comprehensive assessment, documentation, and reporting of mul-
tiple factors that influence the quality and applicability of guideline recommendations.
 2012 Elsevier Inc.
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Open access under CC BY license.1. Background
There is a broad agreement that clinical practice guide-
lines should be ‘‘evidence based’’ but there has been less
agreement on how to achieve this. In response to criticism
that their process of guideline development has not always
been made explicit [1], the World Health Organization
(WHO) recently indicated that wherever possible its guid-
ance should be supported by rigorous reviews of the evi-
dence that has been critically appraised using the GRADE
(Grading of Recommendations Assessment, Development,
and Evaluation) tool [2]. This approach (and others) [3e6]
recognize that the evidence must be viewed in the context
of any relevant local evidence (e.g., microbial resistance pat-
terns), what is feasible in the local clinical setting and what is* Corresponding author. Tel.:þ254-20-2710672; fax:þ254-20-2711673.
E-mail address: nopiyo@nairobi.kemri-wellcome.org (N. Opiyo).
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Open access under CC BY license.acceptable to intended users (health care professionals) and
patients.
Integrating global research evidence with locally relevant
evidence and contextual factors has, however, rarely been
undertaken in an explicit or structured fashion [1,7e9]. This
is a particular problem in low-income countries (LICs). For
newborn and child health, current guidance in LICs is mainly
derived from that provided by WHO and its global partners
(e.g., The United Nations Children’s Fund, UNICEF). The
process of incorporating such guidance into national guide-
lines, often referred to as ‘‘adaptation,’’ is rarely described,
and the roles that value-based judgments and context-
specific information play in developing recommendations
are often not clear.1.1. Aim
We took advantage of efforts in Kenya to revise national
guidelines for newborn and pediatric hospital care to
Table 1. Profile of guideline development panel members
Characteristic Frequency %
Sex
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 A common limitation in guideline development is
the lack of transparency when translating evidence
into recommendations.
 The findings give insights into the many factors
that influence the decision-making process in mul-
tidisciplinary guideline panels.
 GRADE (Grading of Recommendations Assess-
ment, Development, and Evaluation) grid may
aid transparency and provide a mechanism for link-
ing multiple factors that influence the quality and
applicability of guideline recommendations.
 The ‘‘Child Health Evidence Week’’ may provide
an efficient and inclusive rapid guideline develop-
ment model in low-income countries.
examine the process of creating recommendations guided
by the GRADE approach. The aim of the study was to doc-
ument and characterize the discussions that took place
among a multidisciplinary group of health care profes-
sionals who attended a week long meeting to review evi-
dence and make guideline recommendations. Specifically,
we explored the following two topics.
 Which aspects of the quality and nature of research
evidence were key in shaping discussions?
 Which aspects of local contextual factors influenced
the acceptance or rejection of evidence and the final
recommendations?Male 34 49
Female 36 51
Age (yr)
21e30 8 11
31e40 35 50
41e50 14 20
51e60 10 14
Above 60 3 4
Profession
Pediatrician 32 46
Medical officer 11 16
Nursing officer 7 10
Research (research supervision) role 5 7
Trainer of health care workers 5 7
National or provincial role for MoMSs/MoPHS 4 6
Clinical officer 3 4
Pharmacist 2 3
Academic administration 1 1
Number of years as a health care professional
3e7 23 33
8e12 14 20
13e21 16 23
22e40 17 24
Abbreviations: MoMSs, Ministry of Medical Services; MoPHS,
Ministry of Public Health and Sanitation.2. Methods
2.1. Design
This was a descriptive study of the development of na-
tional guidelines for the management of common newborn
and childhood illnesses in Kenya. Discussions between
stakeholders attending a 5-day national guideline develop-
ment workshop (‘‘Child Health Evidence Week’’) held be-
tween 21st and 25th, June 2010, were observed, recorded,
analyzed, and interpreted.
2.2. Participants
The organizers of the guideline development workshop
(that included N.O. and M.E.) used a purposive sampling
approach to select the guideline development panel after
consultations with relevant stakeholders involved in the
provision of newborn and pediatric care services in Kenya.
Briefly, the Kenya Medical Research Institute (KEMRI)-
Wellcome Trust Research Program, working with theMinistry of Medical Services (MoMSs) identified leading
individuals or key institutions of relevance to inpatient
newborn and pediatric care (health worker training
schools; professional associations; international agencies;
national research institutes; and national-, regional-, and
district-level facilities). The MoMSs then sent letters re-
questing these individuals or those nominated by their de-
partmental heads to join the guideline development panel.
The invitation letters described the expected roles of the
participants (e.g., prereading of provided evidence summa-
ries, time commitments) and the research component of the
workshop. Aiming at wide representation, the guidelines
development panel finally consisted of 70 individuals
(Table 1).2.3. Child Health Evidence Week
The ‘‘ChildHealthEvidenceWeek’’was a 1-weekmeeting
of neonatal and pediatric stakeholders gathered to develop
evidence-based guidelines for the hospital management of
common newborn and childhood illnesses in Kenya [10].
The clinical questions addressed were identified after consul-
tations between KEMRI-Wellcome Trust Research Program,
KenyanMoMSs, technical experts (e.g., localWHO represen-
tatives), and other relevant stakeholders (e.g., practitioners and
professional societies).
The identification process was informed by existing
national guidelines (as outlined in the Basic Pediatric
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was 1) lack of clear policy (e.g., hand washing); 2) contro-
versy on acceptable best practice (e.g., newborn feeding
regimens); or 3) likely need to revise or change existing
recommendations given recent research findings (e.g., ma-
laria). After this process, 11 clinical topics addressing as-
sessment, diagnosis, and treatment of priority newborn
and childhood conditions were identified (Appendix C on
the journal’s Web site at www.jclinepi.com). Evidence
summaries and draft recommendations were prepared for
each of the clinical topics by a core team of 14 researchers
and clinicians working in groups of 2 or 3. Evidence was
summarized and packaged in three formats: systematic re-
views, systematic reviews with summary-of-findings tables,
and ‘‘graded-entry’’ formats (a ‘‘front-end’’ summary of
key information linked to a contextually framed short nar-
rative report plus the full systematic review) (see Appendix
D on the journal’s Web site at www.jclinepi.com, e.g.,
‘‘front-end’’ summary [10]). The evidence summaries were
sent to participants 1 month before the workshop.
Participants were introduced to the GRADE approach
and the proposed procedures for the development of recom-
mendations on the first day of the workshop. During the
subsequent days, the core team members made presenta-
tions on the evidence underlying proposed recommenda-
tions, using the PICO (Patient, Intervention, Comparator,
Outcome) format and GRADE method to summarize the
quality of the evidence and introduce possible additional
considerations that might impact on the strength of recom-
mendations. Each presentation was followed by a facilitated
discussion. This initially focused on the formal evidence
presented and subsequently, after presenting a draft recom-
mendation, the wider issue of locally appropriate recom-
mendations. Draft recommendations were then amended
where necessary, and participants invited to vote for or
against proposed recommendations. The voting process
was aided by a modified GRADE grid [12], a scaled polling
table that allows participants to anonymously record their
approval or disapproval of a proposed recommendation
(Appendix A). Votes were counted and fed back to partic-
ipants using power point to display bar graphs of the results
allowing participants a final, short discussion before confir-
mation of a final recommendation. The presentation, dis-
cussion, revision of wording of recommendation, and
voting took approximately 2 hours for each of the clinical
topics addressed. The deliberative process was facilitated
by one, nonvoting investigator (M.E.).2.4. Data collection
Three investigators (A.F., S.S., and N.M.) independently
observed and recorded comments made during the full work-
shop, focusing on discussions about research evidence, prac-
titioner experiences and values, and context-specific issues
that might influence acceptability and implementation of
proposed recommendations.2.5. Data analysis
Three investigators (A.F., S.S., and N.M.) independently
reviewed their field notes of panel discussions, and grouped
comments into a number of clusters. Groupings were
guided by previously identified criteria for assessing the ap-
plicability of systematic review evidence [13]. Themes
emerging from these initial, independent analyses were
then compared and discussed iteratively among the investi-
gators (A.F., S.S., N.M., and N.O.) until a first common set
of descriptive themes was identified. For each main theme,
we identified related subthemes that provided more depth
and detail to our description of the content of the discus-
sions. A table summarizing these initial themes and sub-
themes was then prepared by one of the investigators
(N.O.); the other investigators (S.S., N.M., and A.F.) com-
mented on this draft and a final set of themes (supported by
extracts from the field notes) was arrived at. Further explor-
atory analysis was completed by tabulating the frequency
of aspects of the identified themes for each of the clinical
topics. Disagreements were discussed and resolved by con-
sensus after a review of the field notes.
2.6. Ethics
Ethical approval for the conduct of this study was
granted by the KEMRI scientific committee and National
Ethics Review Committee in Kenya (SSC Protocol No
1770). The project was also presented to the Norwegian
Regional Committee for Medical and Health Research
Ethics, which did not find ethical clearance necessary for
this type of study.3. Results
Overall, our observations of the deliberative process
showed broad participation with most of the participants
actively contributing in the debates. Outcomes of the deliber-
ative process are illustrated with the pneumonia recommen-
dation, where the panel voted against the proposal to replace
benzyl penicillin/ampicillin with oral amoxicillin for the
treatment of severe pneumonia despite moderate quality ev-
idence suggesting equivalence between the treatments and
additional factors favoring amoxicillin (e.g., lower cost,
more convenient twice daily dosing (see Appendices A
and B)). This unexpected voting outcome was probably be-
cause of the indirectness of the evidence [14].
Three key themes (Table 2) emerged from field notes
documenting participants’ discussions:
1. ‘‘Referral to other evidence to support or refute a pro-
posed recommendation.’’
2. ‘‘Assessment of the presented research evidence.’’
This category captures comments by the panelists re-
flecting a deeper assessment of the available research
evidence.
Table 2. Clinical topics and themes
Clinical topic
Referral to various
types of evidence Assessment of evidence Assessment of local applicability of evidence
Research
evidence
Clinical
experience
Quality of
evidence
Nature of
intervention
Interpretation
of evidence Feasibility
Local
context
Balance of
benefits/harms
Values and
preferences
Hand washing O d d O O O e O O
Sepsisdclinical signs d d d O O d O d d
Sepsisdantibiotics O d d d O d O d d
Pneumonia O d O O O O O d O
Kangaroo care O O d O O O O O d
Asthma O O d d O O d O d
HIVdpneumonia O d O O O O d d d
Feeding regimens O O O O O O d d d
Malnutritiondfluids O O O O O d d d d
Meningitis O O O O O O O d d
MalnutritiondRTUFs d O O O O O d d O
Abbreviation: RTUFs, ready-to-use therapeutic foods.
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This category captures comments about whether the
available evidence is applicable in the local setting.
The themes and subthemes with quotes from the field
notes as illustrative examples are presented below.3.1. Referral to other evidence to support or refute
a proposed recommendation
3.1.1. Subtheme a) Research evidence
For nine of the 11 clinical topics, participants referred to
other sources of research evidence to support or refute the
draft recommendations (Table 2). This included the poten-
tial benefits and harms associated with treatment options,
estimates of the magnitude of benefit associated with treat-
ments, absence of relevant evidence, and inconclusive evi-
dence about the effectiveness of treatment options:‘‘Studies have shown that aminophylline is not better
than salbutamol’’ (Asthma)
‘‘To demonstrate superiority of amoxicillin over
co-trimoxazole, what is the absolute effect?’’
(Pneumonia)
‘‘We had a study at Kenyatta [National Referral Hos-
pital]. We did 8-hour Kangaroo care per day. Com-
paring with conventional care, we found difference
in growth of babies, length of stay was a little bit
shorter’’ (Kangaroo caredunpublished report)The absence of relevant evidence and inconclusive state
of evidence were frequently noted as reasons for partici-
pants’ inability to cast a vote based on sound evidence
for or against proposed recommendations:‘‘We cannot say, [it] has not been tested. We are sav-
ing lives in the short-term. It is hard to act on this in-
conclusive evidence’’ (HIV-Pneumonia)‘‘Should we even give a recommendation? Given the
evidence, there is not enough to provide guidance.
The earlier concerns may be valid, we do not know.
So perhaps we should not change’’ (Malnutrition)
‘‘I beg to differ. We cannot apologize to these two pa-
tients if they die and say, we did not have the evi-
dence’’ (Asthma)3.1.2. Subtheme b) Clinical experience
Comments reflecting clinician’s experiences with pro-
posed treatment options were observed in six of the 11 clin-
ical topics (Table 2), and included experiences with routine
clinical impacts of aspects of care, practical difficulties as-
sociated with treatments, and patient’s acceptability of pro-
posed treatments:‘‘In private sector I have experienced that you dis-
charge already at 1.5 kg with Kangaroo care, and
they seem to do well’’ (Kangaroo care)
‘‘I am worried about taking out aminophylline. I had
a patient last week in status asthmaticus who I am
convinced survived only because of the aminophylline
infusion we gave him’’ (Asthma)
‘‘In practice we use ready-to-use therapeutic foods
[RTUFs] because we do not have F100. And it seems
to be well accepted. If there are problems with the
child taking it we mix e.g. with porridge’’ (Severe
malnutritiondRTUFs)Of note, accounts of clinician’s experiences were ob-
served more frequently in clinical conditions where exist-
ing practices were highly varied (e.g., initiation of feeds
in sick newborns) and where the current research evidence
base was weak or inconclusive (e.g., RTUF therapy used
early among inpatients for severe malnutrition).
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3.2.1. Subtheme a) Quality of body of evidence
A range of issues reflecting participants’ scrutiny of the
credibility of the evidence was noted in five of the 11 clinical
topics (Table 2), and included sample size (power) issues,
adequacy of available evidence on patient-relevant outcomes
(e.g., mortality data), study execution (e.g., reliability of find-
ings given premature study termination), adequacy of partic-
ipant follow-up period, appropriateness of the study
population (e.g., limited generalizability from recruiting in-
patient populations), and measurement and selection of out-
comes (e.g., potential biases associatedwith lack of blinding):‘‘The numbers were small in this study, giving us
power problems. And the unblinding gives us a prob-
lem with interpretation’’ (Neonatal feeding regimens)
‘‘The trial was stopped early. Should we try and find
out the reasons for the high mortality?’’ (Malnutrition)
‘‘Is there mortality data on severe pneumonia?’’
(Pneumonia)
‘‘In the absenceof goodquality evidence are there other
good reasons for adopting the policy?’’ (Pneumonia)
‘‘Selection bias of only studying children in hospital’’
(HIV-Pneumonia)Opinions diverged more frequently in clinical conditions
where the quality of evidence was low (e.g., fluid resuscita-
tion in severe malnutrition).3.2.2. Subtheme b) Nature of interventions
Comments seeking clarification of the features, or criti-
cism of, the interventions being discussed were observed in
nine of the 11 clinical topics (Table 2). Aspects discussed
included definitions of the interventions, intensity of inter-
ventions, descriptions of any cointerventions, techniques
relating to how the interventions were delivered, and the
content of interventions:‘‘What is the maximum duration of Kangaroo care?’’
(Kangaroo care)
Clarification required on sequencedwash/ dry/
use alcohol hand rub (Hand washing)
Question asked if inotropic support or mechanical
ventilation were used: answer ‘‘no’’ (Malnutrition)
‘‘Is ciprofloxacin recommended as p.o. [orally] or i.v.
[intravenously]’’ (HIV-Pneumonia)
‘‘For those on breast milk, were they on plain or with
fortifier’’ (Neonatal feeding regimens)‘‘The various fluids have different components, and
we have no research to guide as to which is the bet-
ter’’ (Malnutrition)3.2.3. Subtheme c) Interpretation of evidence
Comments alluding to differences in participants’ inter-
pretation of evidence were observed in all clinical topics
(Table 2), and included various opinions regarding: sub-
group of populations to which results apply, range of factors
explaining differences in study results, and outcome defini-
tions. Additional comments highlighted challenges in the
interpretation of study findings, for example, inconsistency
of individual and pooled study results:‘‘In these studies you are lumping all malnourished
shock patients together, and this is a problem. There
are likely to be important subgroups’’ (Malnutrition)
‘‘Clarification on Papua New Guinea Study.showed
no difference yet combination showed overall benefit
of penicillinþ gentamicin vs. chloramphenicol’’
(Pneumonia)
‘‘What about the morbid condition of the childdwas
this considered?’’ (Kangaroo care)
‘‘What was the definition of treatment failure?’’
(Pneumonia)
‘‘The Duke study had a similar sample size to the
Asghar study yet was unable to show a difference of
effect’’ (Pneumonia)
‘‘Given different patterns of resistance for different
age groups, perhaps recommend cephalosporin for
under 2-year olds, and penicillin plus chlorampheni-
col for the older ones?’’ (Meningitis)3.3. Assessment of the local applicability of evidence
3.3.1. Subtheme a) Feasibility (implementation) issues
Reference to the likely barriers and facilitators to effec-
tive implementation (adoption) of the proposed treatment
options were observed in eight of the 11 clinical topics
(Table 2). Key factors discussed included costs of interven-
tions, resource availability (including training), logistical is-
sues, physical barriers, practical difficulties, and compliance
issues. Also, observed were views related to adaptations re-
quired to facilitate effective delivery of proposed
recommendations:‘‘The science is there, fine. But if we change the rec-
ommendations we will need much training, for exam-
ple, on the differentiation between the various
severities of pneumonia’’ (Pneumonia)
967N. Opiyo et al. / Journal of Clinical Epidemiology 65 (2012) 962e969‘‘I think feasibility is major issue. A mother who has
just delivered needs so many other things, and having
a baby with oxygen, fluids.’’ (Kangaroo care)
‘‘My concern is with the availability of IV [intrave-
nous] salbutamol. If we take out aminophylline we
have nothing’’ (Asthma)
‘‘Getting vascular access will be difficult for people
with limited training’’ (Neonatal feeding regimens)
‘‘Compliance for amoxicillin could be a problem’’
(Pneumonia)
‘‘.incubators are expensive and Kangaroo care will
save money and space’’ (Kangaroo care)3.3.2. Subtheme b) Knowledge of local clinical context
Comments where participants referred to knowledge
about locally relevant practice-setting factors were observed
in five of the 11 clinical topics (Table 2). This included aware-
ness of local antimicrobial resistance patterns, local preva-
lence of febrile illnesses, and nature of available clinical
skills:‘‘The risk of development of resistance across 3rd
generation cephalosporins is highly relevant also in
our setting, as we have experienced at Kenyatta hos-
pital where resistance has emerged’’ (Neonatal
sepsisdAntibiotics)
‘‘Many babies we receive at Kenyatta [National
Referral Hospital] are hypothermic’’ (Kangaroo care)
‘‘Nyanzadsalmonella common in malaria endemic
areas’’ (Meningitis)
‘‘Outpatients in Kenya are staffed by clinical officers
who are familiar with outpatient IMCI [Integrated
Management of Childhood Illnesses]’’ (Neonatal
sepsisdClinical signs)3.3.3. Subtheme c) Balance of benefit and harms
Comments reflecting judgments about likely benefits
and harms of alternative treatments were observed in three
of 11 clinical topics (Table 2), and included comparison of
different types of benefits associated with treatments, likely
benefits and harms, and considerations of benefits of treat-
ments vs. resource consumption. Lack of cost data for most
interventions seemed to limit explicit judgments about their
net value:‘‘Effective, safe, and accessible are the key compo-
nents. If they are equally effective and safe, then
accessibility is the issue’’ (Asthma)‘‘The issue here, as I understand it, is not effective-
ness but safety and toxicity.and the issue is not cost,
both are cheap’’ (Asthma)
‘‘Costs of preparation of alcohol hand rub may be
overweighed by costs of installing running water in
all hospitals’’ (Hand washing)
‘‘Should consider costsddirect costs of good hand
hygiene as well as money spent on morbidity due to
poor hand hygiene’’ (Hand washing)3.3.4. Subtheme d) Clinician values, preferences, and
acceptability
References to health worker perspectives, attitudes, cul-
tural issues, preferences, and acceptability of proposed in-
terventions were observed in four of the 11 clinical topics
(Table 2):‘‘My impression is that the attitude of the health pro-
fessionals is an important factor’’ (Asthma)
‘‘Personal preference of medicated soaps due to the
perfume’’ (Hand washing)
‘‘Need to consider cultural issues, e.g., uptake of
alcohol hand rubs for Muslims’’ (Hand washing)
‘‘Acceptability, F100 may not appear as sufficient
to give to an older child as is just milk. RTUF is
solid, so potentially more acceptable’’ (Severe
malnutritiondRTUFs)4. Discussion
The realization that failure to use research findings in
health care has a negative impact on patient’s care has
led to an increased emphasis on identifying ways to transfer
evidence into practice. The Bellagio Child Survival Series
published in 2003 and the Lancet Neonatal Survival Series
published in 2005 identified low-cost interventions with
proven effectiveness for improving neonatal survival
[15e17]. It is estimated that 35e66% of childhood and
neonatal deaths in resource-poor settings could be pre-
vented if there was high coverage of such interventions.
One of the barriers to implementing these interventions is
accessibility to and use of research evidence by policy
makers and other intended users. In this study, we explored
how research evidence and the related contextual issues in-
form the development of guideline recommendations in
Kenya. A spectrum of factors were considered, these in-
clude the research evidence, implementation factors, and
clinician values. The ‘‘Child Health Evidence Week’’ was
a useful deliberative forum for disseminating key messages
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cussions on research and context-specific data and values,
and discussing draft recommendations during multidisci-
plinary guideline development.
The method for developing guidelines during the ‘‘Child
Health Evidence Week’’ differed from the way guidelines
are developed by established institutions in high-income
countries [5,18]. Unlike these institutions, we had a larger
panel (70 participants), a broader scope (11 clinical topics),
and less time for deliberation (a 5-day meeting). Although
such large panel sizes may limit individual participation
rates, our observations revealed fairly balanced contribu-
tions owing probably to effective facilitation by an experi-
enced, neutral chairperson. Further likely individual biases
were minimized through the use of anonymous voting tool
(GRADE grid) to reach consensus. We believe our rela-
tively large panel was well suited to the broad focus, rapid
nature of our task, and the need for inclusiveness in our
guideline development process. Overall, our approach
resulted in rapid production of evidence-based care recom-
mendations on a broad package of interventions applicable
in Kenya. With further refinement, this method may pro-
vide an efficient and inclusive guideline development
model for use in other LICs.
Our observations revealed important challenges in the
translation of evidence into recommendations. These in-
cluded a lack of evidence, low quality or inconclusive evi-
dence, limited cost data, inadequate reporting of features of
treatments examined (e.g., durations and roles of supportive
care), and differences in panelists’ interpretation of research
literature. This last challenge can be an additional barrier to
the timely achievement of consensus in multidisciplinary
panels. Similar challenges have been documented in related
studies [9,19,20]. Addressing these challenges may require
a consensus-based process for deriving recommendations
where relevant evidence is lacking or inconclusive [21,22],
attention to details of aspects of care under consideration
in evidence reviews (e.g., for a drug intervention, the dose,
route, timing, and duration of administration needs to be re-
ported) [23,24], and training of panel members in research
synthesis relevant to guideline development.
Explicit discussions focusing on trade-offs between likely
benefits, harms, and budget impacts of treatments were
sparse. This confirms previous findings that the net value of
treatments (despite being an important determinant of pa-
tient’s choices and preferences) is frequently overlooked by
guideline development panels [25e27]. Similarly, despite
the value of information about patient’s experiences with
aspects of care (e.g., patients may attach different values to
treatment outcomes) [28e30], explicit consideration of pa-
tient’s perspectives (or their surrogates such as parents and
caretakers) was rarely observed. A possible reason for this
was the absence of patient’s or consumer’s representatives
in the convened panel (a shortcoming of our panel selection).
Still, a number of practical difficulties remain concerning the
feasibility and effectiveness of patient’s and consumer’srepresentation in guideline development panels [31e33].
Further studies are needed to define optimal presentation of
patient-relevant information, and how best to incorporate
patient’s perspectives in the guideline development process
especially in low-income settings.
The strengths of the present study include taking into ac-
count diverse opinions and experiences expressed by the
multidisciplinary panel, the large panel size, whichmay have
improved transparency, our real-time documentation of the
decision-making process, and independent data collection
and review of field notes by three investigators to minimize
bias and error. Recognized limitations include the possible
influence of professional status and expertise of panel mem-
bers on aspects of evidence discussed (e.g., dominance of
discussions by ‘‘powerful’’ members may skew viewpoints
[34,35]), and lack of explicit documentation of panelists’
potential financial and intellectual conflicts of interest [36].5. Conclusions
The present study gives insight into the many factors
that influence the decision-making process in multidisci-
plinary guideline development groups. The findings also
suggest that the process of the ‘‘Child Health Evidence
Week’’ combined with the GRADE grid may aid transpar-
ency in the deliberative process of multidisciplinary guide-
line development groups in low-income settings, and
provide a mechanism for comprehensive assessment, docu-
mentation, and reporting of the many factors that influence
the quality and applicability of evidence-based guideline
recommendations. Further studies on systematic methods
to improve transparency and the rigor of how recommenda-
tions are derived from multiple evidence sources during
guideline development are needed. In addition, a prospec-
tive study that assesses the impact of these methods for
guideline development on patient’s outcomes is key.Acknowledgments
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